In this second installment of KDIGO’s three-part podcast series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), welcomes Barry Freedman, MD (Wake Forest University School of Medicine, United States) for a practical discussion on patient management.

They examine how APOL1 risk variants influence progression, review current therapeutic approaches, and explore emerging targeted treatments designed to improve care and outcomes for affected individuals.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/


This podcast was supported by Vertex Pharmaceuticals.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör KDIGO Communications. Innehållet i podden är skapat av KDIGO Communications och inte av, eller tillsammans med, Poddtoppen.